NOVORAPID FLEXPEN INJECTION 100 uml Singapore - Engels - HSA (Health Sciences Authority)

novorapid flexpen injection 100 uml

novo nordisk pharma (singapore) pte ltd - insulin aspart - injection - 100 u/ml - insulin aspart 100 u/ml

NOVORAPID PENFILL INJECTION 100 uml Singapore - Engels - HSA (Health Sciences Authority)

novorapid penfill injection 100 uml

novo nordisk pharma (singapore) pte ltd - insulin aspart - injection - 100 u/ml - insulin aspart 100 u/ml

Mytolac Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

mytolac

boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg - solution for injection - 120 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 120 mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Mytolac Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

mytolac

boucher & muir (new zealand) limited t/a bnm group - lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg - solution for injection - 60 mg - active: lanreotide acetate 27.3%{relative} equivalent to lanreotide 60mg excipient: acetic acid water for injection - indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. - the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. - the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.